Ovarian Cancer: Update Bulletin [January 2018] [Report Updated: 01012018] Prices from USD $1095

This edition presents key opinion leader KOL views on recent developments in the ovarian cancer market. Topics covered include: US Food and Drug Administration FDA acceptance for Genentech's supplemental Biologics License Application sBLA for Avastin bevacizumab and chemotherapy, followed by Avastin alone, in the frontline setting; EU approval of Zejula niraparib; Tesaro/Merck Co. for the treatment of recurrent ovarian cancer, irrespective of BRCA mutation or biomarker status; Clovis's supplemental New Drug Application sNDA granted Priority Review in the US for rucaparib Rubraca as a maintenance therapy for platinumsensitive, recurrent ovarian cancer and for women showing a complete or partial response to platinum chemotherapy, with no requirement for diagnostic testing.

Business Questions:

What are KOL's current views on the amyloid theory of AD?

What are the KOLs' opinions on Avastin seeking approval in the frontline setting?

How is Avastin currently used and how is that going to change following approval as a frontline therapy?

Do the KOLs believe there any barriers to using Avastin as a frontline treatment?

What is the reaction from the experts following approval of Zejula, irrespective of BRCA mutation status?

Is Zejula likely to displace other PARP inhibitors already available on the market for the treatment of ovarian cancer?

How do the KOLs view the adverse events reported from Phase III trials with Zejula?

Should Rubraca's sNDA receive FDA approval, how likely is the drug to gain extensive market share ahead of its competitors?

What is the view of the experts on having three PARP inhibitors for the treatment of ovarian cancer?

Original Article: Ovarian Cancer: Update Bulletin [January 2018] [Report Updated: 01012018] Prices from USD $1095

More From BioPortfolio on "Ovarian Cancer: Update Bulletin [January 2018] [Report Updated: 01012018] Prices from USD $1095"